The clinical benefits of immune checkpoint inhibitors for thymic carcinomas Source: International Congress 2018 – Clinical management of pleural malignancies, including mesothelioma Year: 2018
Management of pulmonary toxicity associated with immune checkpoint inhibitors Source: Eur Respir Rev, 28 (154) 190012; 10.1183/16000617.0012-2019 Year: 2019
Immune checkpoint inhibitors in lung cancer Source: International Congress 2016 – GR3 Scientific Grand Round: precision medicine Year: 2016
Predictive biomarker of immune checkpoint inhibitors efficacy Source: New biomarkers, molecules and therapeutic sequences for non small cell lung carcinoma in the era of precision medicine Year: 2019
The role of fibrocyte-like cells in combination treatment of immune checkpoint inhibitor with antiangiogenic agents Source: Virtual Congress 2020 – Novel directions in pleural disease: bench to bedside Year: 2020
Emerging concern of infectious diseases in lung cancer patients receiving immune checkpoint inhibitor therapy Source: International Congress 2017 – Lung cancer: clinical research on exhaled breath, clinical trials in advanced NSCLC and real-life appraisals of immunotherapies Year: 2017
Pulmonary complications of immune checkpoint inhibitors in patients with nonsmall cell lung cancer Source: Eur Respir Rev, 28 (153) 190058; 10.1183/16000617.0058-2019 Year: 2019
Evaluation of serial interferon-gamma release assay testing in lung cancer patients treated with immune checkpoint inhibitors Source: Virtual Congress 2021 – Challenges and advances in the diagnosis and clinical management of tuberculosis Year: 2021
From ineffective tumor immune response to immunomodulation in lung cancer Source: ERS Research Seminar 2017 – Immunotherapy: a new standard of care in thoracic malignancies? Year: 2017
Histone deacetylase inhibition significantly augments human mesothelioma cellular response to chemotherapeutic agents Source: Eur Respir J 2001; 18: Suppl. 33, 396s Year: 2001
Relationship between pneumonitis induced by immune checkpoint inhibitors and the underlying parenchymal status: a retrospective study Source: ERJ Open Res, 6 (1) 00165-2019; 10.1183/23120541.00165-2019 Year: 2020
Rationale and targets of immunotherapy in thoracic malignancies Source: International Congress 2016 – Immunotherapy: the lethal weapon against thoracic malignancies? Year: 2016
Preliminary evaluation of serial interferon-gamma releasing assay testing in NSCLC patients treated with immune checkpoint inhibitors Source: Virtual Congress 2020 – Tuberculosis: part 2 Year: 2020
Increased reporting of fatal pneumonitis associated with immune checkpoint inhibitors: a WHO pharmacovigilance database analysis Source: Eur Respir J, 55 (6) 2000038; 10.1183/13993003.00038-2020 Year: 2020
NTHi-induced inflammation activates the PD-1 immune checkpoint in the tumor microenvironment Source: International Congress 2018 – Lung cancer: novel molecular markers and mechanisms Year: 2018
Immune-related adverse effects of checkpoint blockers Source: International Congress 2017 – Lung cancer immunotherapy Year: 2017
The status of populations of cell-mediated lung immunity effectors after chemotherapy of experimental MDR tuberculosis Source: Eur Respir J 2005; 26: Suppl. 49, 656s Year: 2005
Synergistic anti-tumor effects of vandetanib, an inhibitor of VEGFR and EGFR tyrosine kinase inhibitor, combined with cytotoxic agents in lung cancer cell lines Source: Annual Congress 2010 - Treatment of lung cancer Year: 2010